Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ingaron for Prevention of ARVI and COVID-19
NCT05054114Completed
- Sponsor
- SPP Pharmaclon LTD
- Start
- Dec 2020
- Primary completion
- May 2021
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Randomised, open-label trial of Ingaron in coronavirus disease 2019 (COVID-19) and acute respiratory viral infection (ARVI) (2 arms), sponsored by SPP Pharmaclon LTD. Primary endpoint: The Proportion of Patients With Acute Respiratory Viral Infections, Including COVID-19 at 28 days. Started Dec 2020; status: completed.
02
Drugs
Ingaron
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory viral infection (ARVI)
Beyond the preview
Go deeper on NCT05054114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05054114.